2024
Extended-Release 7-Day Injectable Buprenorphine for Patients With Minimal to Mild Opioid Withdrawal
D’Onofrio G, Herring A, Perrone J, Hawk K, Samuels E, Cowan E, Anderson E, McCormack R, Huntley K, Owens P, Martel S, Schactman M, Lofwall M, Walsh S, Dziura J, Fiellin D. Extended-Release 7-Day Injectable Buprenorphine for Patients With Minimal to Mild Opioid Withdrawal. JAMA Network Open 2024, 7: e2420702. PMID: 38976265, PMCID: PMC11231806, DOI: 10.1001/jamanetworkopen.2024.20702.Peer-Reviewed Original ResearchConceptsClinical Opiate Withdrawal ScaleExtended-release buprenorphineOpioid use disorderPrecipitated withdrawalOpioid withdrawalOpioid use disorder treatmentCow scoreClinical Opiate Withdrawal Scale scoreAdverse eventsNonrandomized trialsSevere opioid use disorderDays of opioid useOpiate Withdrawal ScaleModerate to severe opioid use disorderFormulation of buprenorphineOpioid use disorder careWithdrawal ScaleUse disorderAssociated with medicationsNonprescribed opioidsPain scoresExtended-releaseInjection painOpioid useAdult patients
2021
High-Dose Buprenorphine Induction in the Emergency Department for Treatment of Opioid Use Disorder
Herring AA, Vosooghi AA, Luftig J, Anderson ES, Zhao X, Dziura J, Hawk KF, McCormack RP, Saxon A, D’Onofrio G. High-Dose Buprenorphine Induction in the Emergency Department for Treatment of Opioid Use Disorder. JAMA Network Open 2021, 4: e2117128. PMID: 34264326, PMCID: PMC8283555, DOI: 10.1001/jamanetworkopen.2021.17128.Peer-Reviewed Original ResearchConceptsOpioid use disorderEmergency departmentBuprenorphine inductionRespiratory depressionAdverse eventsUse disordersUntreated opioid use disorderSerious adverse eventsFurther prospective investigationLength of stayUrban emergency departmentSafety-net hospitalAdvanced practice practitionersElectronic health recordsUnique cliniciansSublingual buprenorphineBuprenorphine doseED visitsED encountersCase seriesED patientsED physiciansSupplemental oxygenMedian lengthUnique patients
2020
Exenatide extended release in patients with type 1 diabetes with and without residual insulin production
Herold KC, Reynolds J, Dziura J, Baidal D, Gaglia J, Gitelman SE, Gottlieb PA, Marks J, Philipson LH, Pop‐Busui R, Weinstock RS. Exenatide extended release in patients with type 1 diabetes with and without residual insulin production. Diabetes Obesity And Metabolism 2020, 22: 2045-2054. PMID: 32573927, PMCID: PMC8009602, DOI: 10.1111/dom.14121.Peer-Reviewed Original ResearchConceptsExenatide extended releaseResidual insulin productionBeta-cell functionType 1 diabetesC-peptidePlacebo groupPrimary outcomeWeek 12ER groupInsulin productionDetectable C-peptide levelsResidual beta-cell functionGLP-1 receptor agonistsRandomized placebo-controlled trialExtended releaseTotal insulin doseMean HbA1c levelPlacebo-controlled trialC-peptide levelsDetectable levelsCell functionShort-term improvementHbA1c levelsStudy drugAdverse events
2019
Integrated stepped alcohol treatment for patients with HIV and alcohol use disorder: a randomised controlled trial
Edelman EJ, Maisto SA, Hansen NB, Cutter CJ, Dziura J, Deng Y, Fiellin LE, O'Connor PG, Bedimo R, Gibert CL, Marconi VC, Rimland D, Rodriguez-Barradas MC, Simberkoff MS, Tate JP, Justice AC, Bryant KJ, Fiellin DA. Integrated stepped alcohol treatment for patients with HIV and alcohol use disorder: a randomised controlled trial. The Lancet HIV 2019, 6: e509-e517. PMID: 31109915, PMCID: PMC7161741, DOI: 10.1016/s2352-3018(19)30076-1.Peer-Reviewed Original ResearchConceptsAlcohol use disorderWeek 24Use disordersAlcohol treatmentAdverse eventsNumber of drinksTreatment medicationsPhysician managementAlcohol abuseMental Disorders-IV criteriaAlcohol-related careFormal alcohol treatmentKey exclusion criteriaTimeline followback methodMotivational enhancement therapyTreat populationHIV clinicHIV outcomesPrimary outcomeSpecialty referralsMean ageUS National InstitutesWeek 4Medical conditionsExclusion criteria
2018
Safety of Sports for Young Patients With Implantable Cardioverter-Defibrillators
Saarel EV, Law I, Berul CI, Ackerman MJ, Kanter RJ, Sanatani S, Cohen MI, Berger S, Fischbach PS, Burton DA, Dziura J, Brandt C, Simone L, Li F, Olshansky B, Cannom DS, Lampert RJ. Safety of Sports for Young Patients With Implantable Cardioverter-Defibrillators. Circulation Arrhythmia And Electrophysiology 2018, 11: e006305. PMID: 30520349, DOI: 10.1161/circep.118.006305.Peer-Reviewed Original ResearchConceptsYounger patientsLead malfunctionEnd pointSafety of sportsVentricular fibrillation stormPrimary end pointSecondary end pointsSerious adverse eventsMedical record reviewSerious adverse sequelaeCongenital heart diseaseOccurrence of deathImplantable cardioverter defibrillatorLong QT syndromeAdverse eventsICD shocksAdverse sequelaeClinical outcomesCommon diagnosisMultinational registryRecord reviewVentricular arrhythmiasICD populationMean ageClinical details“To Err Is Human” but Disclosure Must be Taught
Crimmins AC, Wong AH, Bonz JW, Tsyrulnik A, Jubanyik K, Dziura JD, Dodge KL, Evans LV. “To Err Is Human” but Disclosure Must be Taught. Simulation In Healthcare The Journal Of The Society For Simulation In Healthcare 2018, 13: 107-116. PMID: 29346222, DOI: 10.1097/sih.0000000000000273.Peer-Reviewed Original ResearchConceptsError disclosurePractice guidelinesEmergency medicineMedical studentsMedical error disclosurePatient-centered careSenior EM residentsAttending EM physiciansLevels of clinical experienceIncreasing physician experienceProspective cohort studyLevel of trainingImmersive simulation scenariosEM physiciansEM residentsHealthcare providersSafe practice guidelinesPhysician experienceAttending physiciansAdverse eventsCohort studySuboptimal adherenceTotal scorePromote safetyProviders
2015
Extended-Release Guanfacine for Hyperactivity in Children With Autism Spectrum Disorder
Scahill L, McCracken JT, King BH, Rockhill C, Shah B, Politte L, Sanders R, Minjarez M, Cowen J, Mullett J, Page C, Ward D, Deng Y, Loo S, Dziura J, McDougle CJ. Extended-Release Guanfacine for Hyperactivity in Children With Autism Spectrum Disorder. American Journal Of Psychiatry 2015, 172: 1197-1206. PMID: 26315981, DOI: 10.1176/appi.ajp.2015.15010055.Peer-Reviewed Original ResearchConceptsExtended-release guanfacineModal doseGuanfacine groupWeek 8Common adverse eventsAutism spectrum disorderWeeks of treatmentAttention deficit hyperactivity disorderDeficit hyperactivity disorderPlacebo groupAdverse eventsBlood pressurePlacebo subjectsClinical trialsSpectrum disorderPlaceboGuanfacineHyperactivityPulse rateHyperactivity disorderGroup differencesMotor planningWeeksBrief cognitive batteryDisorders
2014
Elevated CK-MB with a Normal Troponin Does Not Predict 30-Day Adverse Cardiac Events in Emergency Department Chest Pain Observation Unit Patients
Safdar B, Bezek SK, Sinusas AJ, Russell RR, Klein MR, Dziura JD, D’onofrio G. Elevated CK-MB with a Normal Troponin Does Not Predict 30-Day Adverse Cardiac Events in Emergency Department Chest Pain Observation Unit Patients. Critical Pathways In Cardiology A Journal Of Evidence-Based Medicine 2014, 13: 14-19. PMID: 24526146, DOI: 10.1097/hpc.0000000000000001.Peer-Reviewed Original ResearchConceptsAdverse cardiac eventsCPU patientsNormal troponinAdverse eventsCardiac eventsMultiple logistic regression modelComposite adverse eventsElevated creatinine kinaseObservation unit patientsSerial troponin testingStandardized chart reviewRetrospective cohort studyAcute coronary syndromeNational Death RegistryCoronary artery diseaseLogistic regression modelsPositive troponinPrior CADRenal insufficientCoronary syndromeHemodynamic instabilityChart reviewCohort studyDeath RegistryIschemic electrocardiogram
2004
Implementation of a Safe and Effective Insulin Infusion Protocol in a Medical Intensive Care Unit
Goldberg PA, Siegel MD, Sherwin RS, Halickman JI, Lee M, Bailey VA, Lee SL, Dziura JD, Inzucchi SE. Implementation of a Safe and Effective Insulin Infusion Protocol in a Medical Intensive Care Unit. Diabetes Care 2004, 27: 461-467. PMID: 14747229, DOI: 10.2337/diacare.27.2.461.Peer-Reviewed Original ResearchConceptsInsulin infusion protocolBlood glucose levelsGlucose levelsBlood glucose valuesIll patientsInfusion protocolMedical intensive care unit patientsGlucose valuesTarget blood glucose levelsMedical intensive care unitIntensive care unit patientsCare unit patientsSignificant adverse eventsIntensive care unitPrimary outcome measurementRelevant clinical variablesNarrow target rangeMICU nursesInsulin requirementsInsulin therapyUnit patientsAdverse eventsGlycemic controlCare unitClinical outcomes